Contents

1 Protein Cooperativity and Wrapping: Two Themes in the Transformative Platform of Molecular Targeted Therapy 1
1.1 Many-Body Problems for the Drug Designer 1
1.2 Cooperative Protein Interactions: The Need for the Wrapping Concept 3
1.3 Poorly Wrapped Hydrogen Bonds are Promoters of Protein Associations 6
1.4 Wrapping Defects Are Sticky 9
1.5 Cooperative Drug–Target Associations: A Window into Molecular Engineering Possibilities 12
References 14

2 Wrapping Defects and the Architecture of Soluble Proteins 17
2.1 How Do Soluble Proteins Compensate for Their Wrapping Defects? 17
2.2 Thermodynamic Support for the Dehydron/Disulfide Balance Equation 22
2.3 Evolutionary Support for the Balance Equation 24
2.4 Wrapping Translates into Protein Architecture 24
References 26

3 Folding Cooperativity and the Wrapping of Intermediate States of Soluble Natural Proteins 27
3.1 Many-Body Picture of Protein Folding: Cooperativity and Wrapping 27
3.2 Hydrogen Bond Wrapping Requires Cooperative Folding . . . 30
3.3 Generating Cooperative Folding Trajectories 32
3.4 Wrapping Patterns Along Folding Trajectories 37
3.5 Nanoscale Solvation Theory of Folding Cooperativity: Dynamic Benchmarks and Constant of Motion 41
3.6 Dehydronic Field Along the Folding Pathway and the Commitment to Fold 45
References 46

Bibliografische Informationen
http://d-nb.info/1000034089

digitalisiert durch DEUTSCHE NATIONAL BIBLIOTHEK

4 Wrapping Deficiencies and De-wetting Patterns in Soluble Proteins: A Blueprint for Drug Design 49
4.1 Hydration Defects in Soluble Proteins 49
4.2 Wrapping as a Marker of Local De-wetting Propensity 50
4.3 Dehydrons Are Loosely Hydrated 52
4.4 Displacing Loose Hydrating Molecules: A Blueprint for the Drug Designer 56
References 57

5 Under-Wrapped Proteins in the Order-Disorder Twilight: Unraveling the Molecular Etiology of Aberrant Aggregation . . . 59
5.1 Dehydron Clusters and Disordered Regions 59
5.2 Discrete Solvent Effects Around Dehydrons 61
5.3 Dielectric Modulation of Interfacial Water Around Dehydrons 65
5.4 A Study Case: Dielectric Quenching in the p53 DNA-Binding Domain 67
5.5 Proteins with Dehydron Clusters 69
5.6 Misfolding and Aggregation: Consequences of a Massive Violation of Architectural Constraints 72
References 77

6 Evolution of Protein Wrapping and Implications for the Drug Designer 79
6.1 An Evolutionary Context for the Drug Designer 79
6.2 Wrapping Across Species: Hallmarks of Nonadaptive Traits in the Comparison of Orthologous Proteins 80
6.3 Wrapping and Natural Selection 83
6.4 How Do Humans Cope with Inefficient Selection? 84
6.4.1 Regulatory Patterns for Paralog Proteins 85
6.4.2 Wrapping Deficiency Causes Dosage Imbalance and Regulation Dissimilarity 87
6.5 Human Capacitance to Dosage Imbalances in the Concentrations of Under-Wrapped Proteins 93
6.6 Why Should the Drug Designer Be Mindful of Molecular Evolution? 94
References 95

7 Wrapping as a Selectivity Filter for Molecular Targeted Therapy: Preliminary Evidence 97
7.1 The Specificity Problem in Drug Design 97
7.2 Ligands as Wrappers of Proteins in PDB Complexes: Bioinformatics Evidence 103
7.3 Poor Dehydron Wrappers Make Poor Drugs 105
7.4 Wrapping as a Selectivity Filter 106
7.5 Wrapping as a Selectivity Filter: An Exercise in Drug Design . 107
7.6 Wrapping-Based Selectivity Switch 113
References 113

8 Re-engineering an Anticancer Drug to Make It Safer: Modifying Imatinib to Curb Its Side Effects 117
8.1 Rational Control of Specificity: Toward a Safer *Imatinib* . . . 117
8.2 Unique De-wetting Hot Spots in the Target Protein Provide a Blueprint for Drug Design 119
8.3 In Silico Assays of the Water-Displacing Efficacy of a Wrapping Drug 125
8.4 High-Throughput Screening: Test-Tube Validation of the Engineered Specificity 125
8.5 In Vitro Assays: Selectively Modulating Imatinib Impact . . . 127
8.6 In Vitro Assay of the Selective Anticancer Activity of the Wrapping Design 131
8.7 Enhanced Safety of the Wrapping Redesign in Animal Models of Gastrointestinal Stromal Tumor 134
8.8 Controlled Specificity Engineered Through Rational Design: Concluding Remarks 139
References 139

9 Wrapping Patterns as Universal Markers for Specificity in the Therapeutic Interference with Signaling Pathways 141
9.1 The Need for a Universal Selectivity Filter for Rationally Designed Kinase Inhibitors 141
9.2 Computational Tool Box for Comparative Analysis of Molecular Attributes Across the Human Kinome 143
9.2.1 Wrapping Inferences on Proteins with Unreported Structure 143
9.2.2 Alignment of Targetable Molecular Features Across the Human Kinome 144
9.3 Is Wrapping Pharmacologically Relevant? A Bioinformatics Analysis 144
9.4 A Target Library for the Human Kinome: Broadening the Technological Basis of Drug Discovery 152
9.5 Useful Annotations of a Library of Specificity-Promoting Target Features 153
9.6 The Dehydron Library as a Technological Resource 159
References 160

10 Fulfilling a Therapeutic Imperative in Cancer Treatment: Control of Multi-target Drug Impact 163
10.1 Is There Really a Case for Promiscuous Drugs in Anticancer Therapy? 163
10.2 Cleaning Dirty Drugs with Selectivity Filters: Basic Insights 165
10.3 Cleaning Dirty Drugs by Exploiting the Wrapping Filter: Proof of Concept 166

10.4 Cleaning Staurosporine Through a Wrapping Modification: A Stringent Test 173
10.5 Systems Biology Insights into Wrapping-Directed Design of Multi-target Kinase Inhibitors 177
10.6 Controlling the Cross-Reactivity of Sunitinib to Enhance Therapeutic Efficacy and Reduce Side Effects 179
10.7 Is a Paradigm Shift in Drug Discovery Imminent? 183
References 184

11 Inducing Folding By Crating the Target 187
11.1 Induced Folding: The Bête Noire of Drug Design 187
11.2 Wrapping the Target: A Tractable Case of Induced Folding 188
11.3 Kinase Inhibitors Designed to Crate Floppy Regions 190
11.4 Steering Induced Folding with High Specificity: The Emergence of the Crating Design Concept 195
References 195

12 Wrapper Drugs as Therapeutic Editors of Side Effects 197
12.1 The Editor Concept 197
12.2 Editing Drugs to Curb Side Effects 198
12.3 Designing a Therapeutic Editor Using the Wrapping Selectivity Filter 203
12.4 Therapeutic Editing: Toward a Proof of Principle 205
12.5 Future Perspectives for the Editing Therapy 208
References 209

13 Wrapper Drugs for Personalized Medicine 211
13.1 Wrapping as a Biomarker in Personalized Drug Therapy . . . 211
13.2 Targeting Oncogenic Mutations with Wrapper Drugs 214
13.3 Closing Remarks 215
References 215

14 Last Frontier and Back to the Drawing Board: Protein–Water Interfacial Tension in Drug Design 217
14.1 Interfacial Tension Between Protein and Water: A Missing Chapter in Drug Design 217
14.2 Disrupting Protein–Protein Interfaces with Small Molecules . 222
References 223

Epilogue 225

Index 227